Galapagos awarded €1.8 million grant

By Elaine Rigoli

Tampa, Fla., July 26 - Galapagos NV has been awarded a €1.8 million government grant supporting the development of biological models for the treatment of rheumatoid arthritis and osteoporosis, both core disease areas for Galapagos' research and development.

As part of this program, Galapagos said it will collaborate with three research and development institutes: the University of Antwerp, the University of Ghent and the Flanders Inter-University Institute for Biotechnology.

The two-year program will focus on developing new biological models that will speed up the drug discovery process. Galapagos will work with the three institutes to develop in-vitro cellular models, in-vivo animal models and ex-vivo human models to evaluate the effectiveness of small molecules to treat rheumatoid arthritis and osteoporosis.

Galapagos is a drug-discovery company located in Mechelen, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.